

The Relationship between the Fibrinogen D Domain Self-Association/Cross-linking Site (γ XL) and the Fibrinogen Dusart Abnormality ($\text{A}\alpha$ R554C-Albumin)

Clues to Thrombophilia in the "Dusart Syndrome"

Michael W. Mosesson,* Kevin R. Siebenlist,* James F. Hainfeld,† Joseph S. Wall,‡ Jeanette Soria,\$ Claudine Soria,|| and Jacques P. Caen||

*University of Wisconsin Medical School, Milwaukee Clinical Campus, Sinai Samaritan Medical Center, Milwaukee, Wisconsin 53233;

†Biology Department, Brookhaven National Laboratory, Upton, New York 11973; ‡Hôpital de l'Hotel Dieu, Paris, France; §Inserm U. 353, Hôpital Lariboisière, Paris, France; and ||Institut des Vaisseaux et du Sang, Paris, France

Abstract

Cross-linking of fibrinogen at its COOH-terminal γ chain cross-linking site occurs in the presence of factor XIIIa due to self-association at a constitutive D domain site (" γ XL"). We investigated the contribution of COOH-terminal regions of fibrinogen $\text{A}\alpha$ chains to the γ XL site by comparing the γ chain cross-linking rate of intact fibrinogen (fraction I-2) with that of plasma fraction I-9, plasmonic fraction I-9D, and plasmonic fragment D₁, which lack COOH-terminal $\text{A}\alpha$ chain regions comprising ~ 100 , ~ 390 , and 413 residues, respectively. The cross-linking rates were $\text{I-2} > \text{I-9} > \text{I-9D} = \text{D}_1$, and indicated that the terminal 100 or more $\text{A}\alpha$ chain residues enhance γ XL site association. Fibrinogen Dusart, whose structural abnormality is in the COOH-terminal " α C" region of its $\text{A}\alpha$ chain ($\text{A}\alpha$ R554C-albumin), is associated with thrombophilia ("Dusart Syndrome"), and is characterized functionally by defective fibrin polymerization and clot structure, and reduced plasminogen binding and tPA-induced fibrinolysis. In the presence of XIIIa, the Dusart fibrinogen γ chain cross-linking rate was about twice that of normal, but was normalized in proteolytic fibrinogen derivatives lacking the $\text{A}\alpha$ chain abnormality, as was reduced plasminogen binding. Electron microscopy showed that albumin-bound Dusart fibrinogen " α C" regions were located in the vicinity of D domains, rather than at their expected tethered location near the fibrinogen E domain. In addition, there was considerable fibrinogen aggregation that was attributable to increased intermolecular COOH-terminal $\text{A}\alpha$ chain associations promoted by untethered Dusart fibrinogen α C domains. We conclude that enhanced Dusart fibrinogen self-assembly is mediated through its abnormal α C domains, leads to increased γ XL self-association and γ chain cross-linking potential, and contributes to the throm-

bophilia that characterizes the "Dusart Syndrome." (*J. Clin. Invest.* 1996. 97:2342–2350.) Key words: fibrinogen • fibrin • factor XIII • plasminogen • thrombophilia

Introduction

Congenital abnormal fibrinogens provide useful tools for correlating abnormal structure with functional aspects of the fibrinogen molecule, and they present an important opportunity to gain insight into the relationship between the molecular abnormality and associated clinical problems, such as thrombophilia. More than 260 familial cases of dysfibrinogenemia had been catalogued as of 1994 (1) and of these, 51 were associated with thrombophilia (2). Fibrinogen Dusart ($\text{A}\alpha$ R554C-albumin) is one of them (3), and the thrombophilia with which it is associated has been termed the "Dusart Syndrome" (4). A second $\text{A}\alpha$ R554C family with the Dusart Syndrome, fibrinogen Chapel Hill III (5), has been described.

Dusart fibrinogen molecules contain disulfide-linked albumin molecules, most of which are bound in the carboxy-terminal region of the $\text{A}\alpha$ chain at $\text{A}\alpha$ 554 (6). Functional defects include reduced plasminogen binding (4), impaired fibrin-dependent plasminogen activation by tPA (7), and abnormal fibrin polymerization (4, 6) and clot structure (3, 6, 8). The abnormal polymerization and fibrin clot structure have been correlated directly with the $\text{A}\alpha$ chain defect, in that proteolytic removal of the abnormal region of the $\text{A}\alpha$ chain normalizes both defects (6). The observation that Dusart thin fiber clot structure and tPA-induced fibrinolysis is normalized in the presence of dextran, led to the suggestion that thrombophilia is attributable to hypofibrinolysis caused by the abnormal clot structure itself (8).

During the course of recent studies on factor XIIIa-mediated fibrinogen and fibrin γ chain cross-linking (9), we identified two constitutive self-association sites in fibrinogen D domains, termed "D:D" and " γ XL", respectively. These sites participate in the process of fibrin(ogen) polymerization (9, 10), and are independent of the well-known constitutive D domain "a" polymerization site ("Da") that participates in fibrin "D:E" assembly by reacting with a thrombin-exposed E domain "A" site ("EA") (11–13) (see Fig. 1). The D:D site promotes end-to-end molecular alignment in assembling fibrils, whereas the γ XL: γ XL interaction results in intermolecular carboxy-terminal γ chain association that facilitates XIIIa-mediated cross-linking.

In the studies presented here, we explored the structures in normal fibrinogen that contribute to γ XL site association and cross-linking, and report that carboxy-terminal regions of $\text{A}\alpha$ chains enhance formation of that site. We also investigated the contribution of the Dusart $\text{A}\alpha$ chains to γ XL site function, and found that the abnormality promotes "pre-assembly" of fibri-

The results of this study were published in abstract form (*Blood*. 1995. 86 [suppl 1]: 76a) and presented in part at the 37th annual meeting of the American Society of Hematology, December 1–5, 1995.

Address correspondence to Michael W. Mosesson, M.D., Sinai Samaritan Medical Center, 945 North 12th Street, Milwaukee, Wisconsin 53233. Phone: 414-283-7744; FAX: 414-283-7477.

Received for publication 8 December 1995 and accepted in revised form 22 February 1996.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/96/05/2342/09 \$2.00

Volume 97, Number 10, May 1996, 2342–2350

nogen molecules and consequent increased cross-linking potential, a phenomenon that probably plays a causal role in the thrombophilia that is associated with the abnormality.

Methods

All chemicals and reagents were the highest purity available from commercial sources. Glycerol was from Fisher Chemical (Fair Lawn, NJ). PMSF, Coomassie Brilliant Blue R250 and Dextran (average mol wt, 35,600) were purchased from Sigma Chemical Co. (St. Louis, MO). Trasylol (aprotinin) was obtained from Miles Inc. (Kankakee, IL). Human α -thrombin (specific activity, 3.4 U/ μ g), glu-plasminogen, and lys-plasminogen were obtained from Enzyme Research Laboratories, Inc. (South Bend, IN). The plasminogens were labeled with 125 I by the iodine monochloride method (14). Plasmin (12.3 U/mg) was prepared by the method of Robbins and Summaria (15). Factor XIII (2460 Loewy U/mg; reference 16) was prepared from human plasma (17). Human serum albumin was obtained from Armour Pharmaceutical Co., Kankakee, IL.

Normal and Dusart fibrinogen fractions I-2 and I-9 were isolated from citrated plasma by glycine precipitation (18) and then further purified (19). Fibrinogen concentrations were determined spectrophotometrically at 280 nm using an absorbance coefficient ($A_{1\text{cm}}^{1\%}$) of 15.1 (20). Normal or Dusart fraction I-9D fibrinogen was prepared from fraction I-2 by incubating fibrinogen (5 mg/ml) with 0.1 U/ml plasmin in 50 mM Tris, 100 mM NaCl, pH 7.5, for 1.5 min at 37°C. The brief digestion was terminated by adding aprotinin (10 U/ml) followed by gel sieving over Sepharose 4B to separate cleaved fragments from core material. The subunit structure of the core fragments was determined by SDS-PAGE (21) on 1.5 mm polyacrylamide slab gels (5% gels, nonreduced samples; 9% gels, reduced samples) (see Fig. 2). As assessed by immunoblot assay, normal and Dusart fraction I-9D fibrinogen each contained only 0.06 mole of intact A α chains per mole fibrinogen (6).

Fragment D₁ was prepared by digestion of normal fibrinogen (10 mg/ml) for 6 h at 37°C with plasmin, 0.1 U/ml, in 0.10 M NaCl, 0.05 M Tris, pH 8.6 buffer containing 10 mM CaCl₂ and 5 mM *N*-ethylmaleimide (NEM). Fragments D₁ and E were separated by anion exchange chromatography on DE-52 (Whatman) (22). Fragment D₁ concentrations were determined spectrophotometrically at 280 nm using an absorbance coefficient ($A_{1\text{cm}}^{1\%}$) of 20.8 (23).

Fibrin polymerization was initiated by the addition of thrombin (0.1 U/ml) and was monitored at room temperature at 350 nm in a Gilford Response recording spectrophotometer. Reaction mixtures contained fibrinogen (normal or Dusart fraction I-2 or I-9D) at 0.5 mg/ml in 50 mM Tris-HCl, 100 mM NaCl, pH 7.4 buffer.

Plasminogen binding experiments were carried out on normal or Dusart fractions I-2, I-9, and I-9D using 125 I-labeled glu- or lys-plasminogen as follows: duplicate solutions containing 25 μ g (0.074 nMol) to 200 μ g (0.58 nMol) fibrinogen in 50 mM Tris, 50 mM NaCl, pH 7.4 buffer containing aprotinin (5 KIU/ml) (final volume, 100 μ l), were clotted by adding thrombin (0.5 U/ml, final), incubated for 1 h at room temperature, and then overnight at 4°C. 125 I-labeled glu- or lys-plasminogen in the Tris-NaCl buffer (final volume, 100 μ l) was added at a final molar ratio to fibrinogen of 10:1, and incubated overnight at 4°C. The resulting clots were synerized, washed four times with buffer, and radioactivity in the clot and clot liquor was determined. The coagulability of normal and Dusart fibrinogen fractions under these conditions was > 90%.

Plasma factor XIII at a concentration of 500 Loewy U/ml in 0.1 M NaCl, 20 mM Hepes, pH 7 buffer containing 0.1–0.5 mM DTT, was activated to XIIIa by adding human α -thrombin (5 U/ml, final concentration), and incubating at 37°C for 30 min. (In comparison experiments in which the DTT concentration in the XIII activation mixture was varied between 0.1 and 0.5 mM, there were no significant differences in subsequent fibrinogen or fibrin cross-linking behavior attributable to the concentration of DTT.) For preparing XIIIa-cross-

linked fibrinogen, thrombin in the activation mixture was inactivated by adding a 10-fold excess of hirudin (Sigma Chemical Co.) (50 U/ml, final concentration). Hirudin-treated XIIIa had no measureable thrombin activity as assessed by its failure to release detectable FPA from fibrinogen (24) at a final XIIIa concentration of 100 U/ml over a 24-h incubation period, or to cleave the fibrinogen A α chain as assessed by SDS-PAGE of reduced fibrinogen specimens (9).

For SDS-PAGE analyses of fibrinogen or fibrin cross-linking, XI-IIa (10 to 100 U/ml, final concentration) containing hirudin-inactivated thrombin or active thrombin (not hirudin treated), was added to a fragment D₁ or fibrinogen solution (1.5 mg/ml, final) in 0.1 M NaCl, 20 mM Hepes, pH 7 buffer containing 10 mM CaCl₂ and incubated at room temperature for up to 24 h. In some experiments human serum albumin was included in the cross-linking mixture at a final concentration of 0.5 mg/ml. At selected intervals, the cross-linking reaction was terminated by adding an equal volume of 5% SDS, 10 mM Tris, 1 mM EDTA, 10% β -mercaptoethanol, pH 8 solution, and the samples subjected to electrophoresis on 8–25% gradient gels in a Phast gel apparatus (Pharmacia/LKB). Densitometric scanning of Coomassie blue-stained gels was carried out at 540 nm in a Gilford Response UV-VIS spectrophotometer. The initial rate of γ chain cross-linking of fibrinogen or fibrin was determined from the ratio of γ dimers to the total γ chain population ($\frac{\gamma\gamma}{\gamma + \gamma\gamma}$) at the earliest sampling time. In the case of fragment D₁, the β and γ subunit bands were not resolved from one another. Therefore, in calculating the γ chain cross-linking rate, the scanned density of the $\beta + \gamma$ position was corrected for the β band contribution by assuming that the specific absorptivity for each component was the same.

Samples of fibrin for transmission electron microscopy (TEM) were prepared from fibrinogen (normal or Dusart; fraction I-2 or I-9D) as 50- μ l drops (50 μ g/ml in 50 mM Tris-HCl, 100 mM NaCl, pH 7.4 buffer). After thrombin addition (0.1 U/ml) and incubation overnight at room temperature, a fibrin clot specimen was picked up on a carbon-coated 200-mesh grid, fixed with glutaraldehyde/tannic acid, stained with uranyl acetate, dehydrated, and critical point dried (24). Samples of fibrin for negative staining were clotted and picked up on grids as described above and negatively contrasted with 2% (wt/vol) uranyl acetate. Electron microscopy was carried out in a Philips 400-T electron microscope at 80 or 120 kV.

Fresh, partially cross-linked fibrinogen for scanning transmission electron microscopy (STEM) was prepared as described (9). Briefly, fibrinogen (1 mg/ml)-XIIIa (25 U/ml or 100 U/ml) mixtures were deposited as 50 μ l drops on a parafilm surface and incubated at room temperature for 5–20 min. At a selected time interval, the specimen was diluted to a concentration of 5 to 10 μ g/ml in 0.1 M NaCl, 20 mM Hepes, pH 7 buffer, 3 μ l injected into a 3 μ l droplet of buffer on a microscope grid, and the specimen allowed to attach to the grid surface for one minute. Fluid on the grid surface was then exchanged 8–10 times with 150 mM ammonium acetate solution, the specimen frozen in liquid nitrogen, freeze-dried, transferred under vacuum to the microscope stage, and imaged at the Brookhaven STEM facility using a 40-kV probe focused at 0.25 nm. Fibrinogen specimens for STEM were prepared from room temperature stock solutions that had been diluted with the Hepes buffer to a final concentration of 2 μ g/ml, applied directly to grids, and processed as described above. Background filtering of digitized STEM images was optimized for contrast and brightness offset by an image processing program (Adobe Photoshop), and the adjusted images downloaded to a GCC Technologies ColorFast film recorder.

Results

Characterizing the fibrinogen constituents that contribute to γ XL self-association. In recent studies concerned with the location of carboxy-terminal γ chain cross-linking sites in assembled fibrin polymers (9), we identified two constitutive D domain self-association sites, γ XL and D:D, respectively, that




Figure 1. Schematic diagram of the fibrinogen molecule illustrating the location of the D domain association sites Da, D:D, and γ XL, and the α C chain carboxy-terminal α C domain. One α C domain is depicted as associating with the E domain. The α C domain in the other α C chain is not associated with the E domain, and has an albumin molecule bound in a position corresponding to Dusart α C R554C. The approximate cleavage site on the α C chain resulting in the $\alpha/$ chain remnant found in fractions I-9, I-9D, or fragment D, respectively, is shown by a dashed arrow.

participate in the assembly of cross-linked fibrinogen and fibrin (Fig. 1). The sites are distinguishable from one another and from the Da site that participates in fibrin fibril assembly through the fibrin D:E interaction. γ XL contains the γ chain cross-linking site (γ 398-406), and is recognized from the observation that in XIIIa-mediated fibrinogen cross-linking, γ chains become cross-linked first to form γ dimers, just as they do in fibrin, albeit at a slower rate. The D:D interaction promotes end-to-end alignment of fibrin(ogen) molecules within a fibril strand, and is distinct from γ XL on several grounds (9), but most notably from the observation that fibrinogen Tokyo II (γ R275C) undergoes XIIIa-mediated fibrinogen and fibrin γ chain cross-linking at the same respective rates as normal (i.e., normal D:E and γ XL: γ XL), yet displays abnormal end-to-end molecular associations (i.e., abnormal D:D site) (10).

To investigate the constituents of the fibrinogen molecule that comprise the γ XL site, we evaluated the γ chain cross-linking rate of fibrinogen and fibrinogen derivatives and fragments that contain the γ chain cross-linking site (Fig. 2). Plasma fraction I-9 fibrinogen, whose α C chains lack carboxy-terminal segments comprising ~ 100 or more residues (25-27), underwent γ chain cross-linking at 68% of the rate of fraction I-2 (0.046/min vs 0.068/min), which contains a very high proportion of intact α C chains (~ 67 kD). Fragment D₁, lacking the 413 residues beyond α A 197 (28, 29), yet retaining the carboxy-terminal γ chain sequence and thus the capability of γ chain cross-linking (30) and of binding to the platelet fibrinogen receptor (31), showed an initial rate of cross-linking (0.018/min) amounting to 26% of that for I-2. Plasmonic fraction I-9D, which contains a smaller residual α C chain population than I-9 (26), mainly lacking segments of ~ 390 residues (28, 32), showed the same initial cross-linking rate as fragment D₁. Overall, these experiments show a progressive reduction of the γ chain cross-linking rate as a function of the α C chain composition, indicating that the carboxy-terminal 100+ residues of α C chains enhance association at the γ XL site.

Normalizing the clotting and plasminogen binding functions of fibrinogen Dusart by removing carboxy-terminal α C chain segments. We previously reported on the polymerization and ultrastructure of Dusart fractions I-2 and I-9D fibrin (6), and we briefly summarize these results here to provide a description of the structure of Dusart fibrin from which carboxy-terminal segments of its α C chains had been removed. As assessed by turbidity measurements, Dusart I-2 fibrin polymerized with a longer lag time and at a much reduced turbidity rate compared to normal I-2 fibrin, confirming an earlier report (4). Electron microscopy of a critical point dried Dusart I-2 fibrin clot showed a branched network of fibers that were thinner than those in normal fibrin. These network structures were

similar to those reported by Collet et al. (8), except they did not branch as extensively. By contrast, Dusart I-9D fibrin polymerized faster than the original I-2 fibrin, but at nearly the same rate as normal I-9D fibrin, which itself polymerized more slowly than the I-2 fibrin from which it had been derived. Clot matrices formed from normal and Dusart fraction I-9D fibrinogen formed networks that were virtually indistinguishable from one another, and were composed of thick fibers showing typical 22.5 nm periodicity.

Previous experiments demonstrated that fibrinogen Dusart bound less plasminogen than normal fibrinogen (4), and possibly as a consequence, showed reduced fibrin-dependent tPA-mediated plasminogen activation (7). In these present experiments, we evaluated plasminogen binding to Dusart plasma fractions I-2 and I-9, and plasmonic fraction I-9D (Table I), and confirmed that there was reduced binding of both glu- and lys-plasminogen to intact fibrin. Plasminogen binding was normalized in Dusart I-9 or I-9D fibrin, both of which lack that portion of the α C chain containing the Dusart structural abnormality.

Cross-linking of Dusart fibrinogen and fibrin. Fibrinogen Dusart γ chains became cross-linked in the presence of XIIIa about twofold more rapidly than did normal fibrinogen γ chains (Figs. 3 and 4). Including albumin (0.5 mg/ml) in the normal fibrinogen cross-linking mixture did not significantly change its




Figure 2. The cross-linking of normal fibrinogen fractions and fragment D₁ by factor XIIIa (100 U/ml). The data shown for I-2, I-9, and fragment D₁ are the mean values of triplicate determinations, and duplicate determinations for I-9D. The γ chain cross-linking rate (ordinate) is plotted as the ratio of γ dimer or $\gamma/$ dimer (fragment D₁) over the total γ or $\gamma/$ chain population ($\frac{\gamma\gamma}{\gamma+\gamma\gamma}$) versus time (min). \circ , I-2; \bullet , I-2 + albumin; \triangle , I-9; \times , I-9D; \square , fragment D₁.

Table I. Plasminogen Binding to Fibrin (mol/mol)

Fibrin	n	glu-plasminogen/fibrin	lys-plasminogen/fibrin
Fraction I-2			
Normal	8	1.6±0.6	3.3±0.7
Dusart	8	0.87±0.2 (P < 0.001)	1.4±0.5 (P < 0.0001)
Fraction I-9			
Normal	2	1.5 (1.51, 1.52)	3.4 (3.3, 3.5)
Dusart	2	1.6 (1.61, 1.62)	3.1 (3.06, 3.14)
Fraction I-9D			
Normal	2	1.6 (1.55, 1.62)	3.2 (3.18, 3.21)
Dusart	2	2.1 (2.05, 2.07)	3.1 (3.01, 3.23)

cross-linking rate (Fig. 2), suggesting that the presence of albumin, per se, does not cause a change in the γ chain cross-linking rate. As is the case for normal fibrinogen, the A α chain cross-linking rate of Dusart fibrinogen was considerably slower than that of the γ chains (9, 33) and showed little, if any, tendency to form A α polymers more rapidly than its normal counterparts. Thus, accelerated XIIIa-mediated cross-linking of Dusart fibrinogen is evidently confined to its γ chain population. In contrast to the accelerated cross-linking rate observed for intact Dusart fibrinogen, Dusart I-9D became cross-linked at about half the rate of normal fibrinogen, but at virtually the same rate as I-9D from normal fibrinogen (Fig. 4).

Fibrin γ chains become cross-linked much more rapidly than those of fibrinogen (9, 10, 33), a rate enhancement that directly reflects D:E driven fibrin fibril assembly. At this level of XIIIa (100 U/ml) and thrombin (1 U/ml), both Dusart and normal fibrin γ chains were completely cross-linked at the earliest sampling time (Fig. 4, lower panel; 1 min), suggesting that the Dusart fibrin D:E interaction is normal. Further support for this conclusion was obtained from a fibrin cross-linking experiment that was carried out at a lower XIIIa (10 U/ml) and thrombin (0.1 U/ml) concentration. Under these conditions of slower fibrin assembly, γ chain cross-linking of intact Dusart and normal fibrin was nearly the same at the 1-min sampling time (80 vs 74%, respectively). The Dusart I-9D fibrin γ chain cross-linking rate was greater than that of Dusart I-9D fibrinogen, no doubt reflecting the effect of the D:E interaction, but the cross-linking rate of Dusart I-9D fibrin did not differ significantly from that of normal I-9D fibrin. Thus, as had been the case for fibrin clot assembly, normalization of the fibrinogen Dusart cross-linking rate can be achieved by removing the regions of its A α chains containing the structural abnormality.

STEM of Dusart fibrinogen and cross-linked fibrinogen. A possible explanation for the acceleratory effect of Dusart fibrinogen on γ XL: γ XL association and cross-linking could lie with the fact that Dusart molecules have an increased self-association tendency due to the A α chain defect. We examined that possibility directly by assessing the structure and distribution of normal or Dusart fibrinogen molecules that had been deposited at a concentration of 2 μ g/ml on carbon films and then imaged by STEM. At this concentration, the particle density of Dusart fibrinogen molecules deposited on the grid surface was robust (Fig. 5 A), and exhibited a clear tendency for molecular clustering. In contrast, normal fibrinogen molecules were relatively sparse and more evenly distributed (Fig. 5 B), and showed only a modest tendency for intermolecular aggre-




Figure 3. SDS-PAGE gels of the cross-linking of Dusart versus normal I-2 fibrinogen in the presence of XIIIa (100 U/ml). The positions of the various reduced fibrinogen subunit chains are indicated; albumin from Dusart fibrinogen molecules migrates in the A α position. Time of cross-linking in minutes.




Figure 4. The γ chain cross-linking rate of Dusart and normal fractions I-2 and I-9D plotted as $(\frac{\gamma\gamma}{\gamma\gamma + \gamma\gamma})$ versus time (min). (Upper panel) Fibrinogen, (lower panel) Fibrin. \circ , Dusart I-2; \square , normal I-2; \bullet , Dusart I-9D; \blacksquare , normal I-9D (XIIIa, 100 U/ml). \triangle , Dusart I-2; \blacktriangledown , normal I-2 (XIIIa, 10 U/ml).




Figure 5. STEM images of Dusart (A) and normal fibrinogen (B) deposited at a concentration of 2 $\mu\text{g/ml}$. The particle density of normal fibrinogen molecules in these fields was 42.7 ± 26.3 per μm^2 ($n = 18$ fields), whereas the density of Dusart fibrinogen molecules was 93.5 ± 24.8 per μm^2 ($n = 17$ fields; $P < 0.0001$). Selected examples of heterodimeric or homodimeric Dusart fibrinogen molecules are shown in the insets to A. Albumin molecules bound to fibrinogen are indicated by arrows. Bar, 50 nm.




Figure 6. STEM images of cross-linked Dusart fibrils (A and B) and normal fibrinogen fibrils (C and D). Dusart fibrinogen and normal fibrinogen were cross-linked at XIIIa concentrations of 25 U/ml and 100 U/ml, respectively. Albumin bound to fibrinogen Dusart molecules are indicated by arrows. Bar, 50 nm.

gation (e.g., occasional end-to-end dimers), as previously described (9). Albumin molecules bound to Dusart fibrinogen were usually easy to identify (arrows, Fig. 5 A) and were most often found in the vicinity of D domains rather than in close proximity to E domains, a finding that extends previous observations on the position of fibrinogen-bound albumin molecules that had been deposited from glycerol-containing solutions (6).

In view of the accelerated γ chain cross-linking of Dusart fibrinogen, we carried out cross-linking of Dusart fibrinogen at lower than usual XIIIa concentrations (25 U/ml versus 100 U/ml). This lower enzyme concentration allowed us to obtain cross-linked samples of sufficiently low viscosity to permit sample dilution and deposition on the microscope grid (Fig. 6). Like normal fibrinogen (C and D), cross-linked Dusart fibrinogen formed elongated double-stranded fibrils (A) and did not show a tendency to branch. (Cross-linked normal fibrino-




Figure 7. The cross-linking rate ($\frac{\gamma\gamma}{\gamma + \gamma\gamma}$) of Dusart versus normal fraction I-2 fibrinogen $\pm 30\%$ dextran in the presence of XIIIa (100 U/ml). (Inset), Fibrin; ○, Dusart I-2; □, normal I-2; ●, Dusart I-2 + dextran; ■, normal I-2 + dextran.

gen fibrils were rarely found in cross-linking mixtures at XIIIa concentrations of 25 U/ml-not shown.) Formation of double-stranded linear fibril structures indicates that D:D interactions in Dusart fibrinogen molecules are normal, as would be expected. In addition, Dusart cross-linked fibrinogen fibrils showed a tendency to associate laterally to form multi-stranded fibers (Fig. 6 B) to a much greater extent than is seen in normal fibrinogen cross-linking mixtures. However, Dusart fibrinogen fibrils differed in subtle ways from their normal counterparts, in that A α chain-bound albumin molecules could sometimes be identified (arrows) protruding from the fibril strands.

The effect of dextran and glycerol on Dusart fibrinogen cross-linking. Collet et al. (8) reported that dextran normalized the structure of the Dusart fibrin clot from a thin fiber matrix to a more coarse and permeable structure containing thicker fibers, concomitant with normalization of the impaired tPA-induced fibrinolysis, an effect that is consistent with the known property of dextran to produce a more coarse fibrin network structure (34–36). To determine whether dextran had a normalizing effect on the cross-linking of Dusart fibrinogen, we evaluated XIIIa-mediated cross-linking in the presence of 30% dextran (Fig. 7). At this level, at which normalization of the abnormal Dusart clot structure was reported to have occurred (8), dextran not only did not reduce the accelerated γ chain cross-linking rate of Dusart fibrinogen, but very likely caused a modest increase in the cross-linking rate ($\sim 10\%$). Dextran had no significant negative effect on the fibrin cross-linking rate (Fig. 7, inset) inasmuch as γ chain cross-linking was complete at the first sampling time (1 min) in each case. Thus, whatever action dextran has on Dusart fibrin, it does not appear to be mediated through modification of γ XL: γ XL associations.

Unlike dextran, which promotes coarse matrix formation, polyhydroxyl compounds like glycerol impair fibrin polymerization and promote formation of thin fiber networks (37, 38). To contrast these opposite effects, we evaluated the effect of 20% glycerol on fibrinogen and fibrin cross-linking (Fig. 8),




Figure 8. The cross-linking rate ($\frac{\gamma\gamma}{\gamma + \gamma\gamma}$) of Dusart versus normal fraction I-2 fibrinogen $\pm 20\%$ glycerol in the presence of XIIIa (100 U/ml). (Inset), Fibrin; \circ , Dusart I-2; \square , normal I-2; \bullet , Dusart I-2 + glycerol; \blacksquare , normal I-2 + glycerol.

and found a marked effect in reducing the γ chain cross-linking rate of both Dusart and normal fibrinogen, and a similar effect in reducing their fibrin γ chain cross-linking rates. These observations indicate that glycerol reduces the γ XL: γ XL association rate, as well as D:E assembly.

Discussion

Fibrin molecules lacking carboxy terminal regions of α C chains form less turbid clots and contain thinner fibers than those formed from intact fibrin (19, 39, 40). Recent studies (32, 41) indicated that a carboxy-terminal α C chain segment (termed " α C") that is associated with the fibrinogen E domain in the native molecule, became untethered as a result of FPB cleavage, thereby becoming available for association with other α C domains in promoting lateral fibrin fiber associations. To explore the α C chain α C self-association phenomenon in relation to the D domain self-association sites, particularly γ XL, we investigated the structural constituents in fibrinogen that contribute to forming the γ XL association site. Normal fibrinogen having intact α C chains showed the fastest rate of γ chain cross-linking, whereas fraction I-9 which lacks carboxy-terminal α C chain segments of ~ 100 residues, showed a reduced γ chain cross-linking rate. Fragment D₁, lacking 413 carboxy-terminal α C chain residues, showed a lower rate of cross-linking than I-9, but the same rate as that for I-9D. These findings indicate that the carboxy-terminal ~ 100 residues of the fibrinogen α C chains contribute to association and cross-linking at γ XL sites, and that the contributory effect extends over an even longer stretch of the α C chains. The effect may be even greater when the " α C" domain is not associated with the E domain, as discussed below with respect to fibrinogen Dusart.

In view of the finding that carboxy-terminal segments of normal α C chains participate in γ XL site function, we evaluated fibrinogen Dusart from this standpoint since its structural abnormality resides in this region. Dusart γ chains were more rapidly cross-linked in the presence of XIIIa than was normal

fibrinogen, but the enhanced activity was normalized in Dusart fractions lacking the carboxy-terminal α C chain abnormality. This indicates that the Dusart α C chain has a significant effect in promoting an increased intermolecular association and potential cross-linking rate at the γ XL site. Furthermore, the Dusart fibrin γ chain cross-linking rate, although more rapid than that of fibrinogen, was the same as that of normal fibrin, thus indicating that the fibrin D:E interaction was not impaired.

STEM images of cross-linked Dusart fibrinogen fibrils confirmed the increased γ XL: γ XL self-association tendency, in that XIIIa-cross-linked Dusart fibrinogen formed longer and more numerous double-stranded fibrils than did normal fibrinogen at a XIIIa level only 25% of that used for normal. The normal structure of Dusart fibrinogen fibrils indicated that the D:D interaction, per se, was normal. Increased self-association was also supported by STEM images of Dusart fibrinogen molecules, which showed a considerable tendency to aggregate compared with normal. Of collateral interest was the finding that albumin bound to Dusart fibrinogen molecules were situated in the vicinity of its D domains, indicating that the carboxy-terminal α C chain was located in this region rather than with the E domain. In contrast to this observation, there is ultrastructural evidence derived from observations of fibrinogen compared with fibrin (32, 41), and data from STEM mass measurements on fibrinogen molecules (42), that the carboxy-terminal α C domain of normal fibrinogen tends to be situated at or near the E domain. Of note in this regard is that release of the α C region from the E domain after thrombin cleavage of FPB, is associated with increased lateral fibrin fibril association (41). Conversely, the absence of this domain (19, 32, 39-41) or competitive inhibition of its binding function (32), results in decreased lateral fibrin fibril association. Dissociation of α C domains in Dusart fibrinogen evidently involves at least the abnormal α C domains in affected heterozygotic individuals ($\sim 50\%$), an amount that far exceeds the level of α C dissociation ($< 10\%$) observed in normal fibrinogen molecules (32). We interpret these findings as suggesting that increased α C domain dissociation in Dusart fibrinogen molecules leads to increased intermolecular association, and concomitantly or consequently, to enhanced γ XL: γ XL association. The tendency for molecular "pre-assembly" due to demodulation of the E domain binding activity of α C may be a most important factor contributing to the thrombophilia that accompanies the "Dusart Syndrome" (4, 5). Although there is no evidence that premature dissociation of α C domains occurs in any other abnormal fibrinogen, it is very likely that investigation of existing "thrombophilic" dysfibrinogens along the lines developed in this study will reveal other examples of this phenomenon.

In fibrinogen Dusart, the α A 554 Arg to Cys substitution, the concomitantly disulfide-bound albumin, or a combination of the two has an effect on fibril assembly that results in low turbidity clots containing thinner than normal fibers (3, 6, 8). It is not clear on experimental grounds how these abnormalities contribute to thin fibrin fiber formation. It appears to us that this may be directly related to the tendency for increased Dusart fibrinogen self-association before its conversion to fibrin, an event that may lead to enhanced linear fibrinogen fibril formation and concomitant reduction in "trimolecular" fibrin network branch junctions (43, 44). Dextran, which is known to induce a thick fiber network structure (34-36), normalized the abnormal Dusart thin fiber structure (8), but ac-

celerated Dusart fibrinogen γ chain cross-linking was not normalized (Fig. 7), and dextran had no measureable effect on fibrin γ chain cross-linking. Thus, whatever action dextran has on Dusart fibrin fiber formation, it does not appear to be mediated through modification of the γ XL: γ XL or D:E association. Glycerol on the other hand, which impairs fibrin polymerization and promotes formation of thin fiber networks (37, 38), had a marked effect in reducing the γ chain cross-linking rate of both Dusart and normal fibrinogen and fibrin, suggesting that unlike dextran, glycerol impairs both γ XL: γ XL and D:E interactions.

Hypofibrinolysis has been proposed as the main causal factor for thrombophilia in the Dusart Syndrome (8), an effect that may be related to its thin 'fiber' clot structure, a type of network structure that reportedly lyses at a slower rate than 'coarse' clots containing thick fibers (45, 46). Enhanced thin fiber formation resulting directly from increased self-association of Dusart fibrinogen molecules and enhanced linear fibril formation, could account for this effect. Another factor, however, contributing to reduced fibrinolysis may be that Dusart fibrinogen binds less plasminogen than normal (reference 4, Table I) and consequently displays reduced fibrin-enhanced plasminogen activation (7). Since the abnormal functions of fibrinogen Dusart are normalized when the abnormal A α chain region is removed, it would seem that therapy directed at enhancing fibrinolysis, by promoting proteolytic release of carboxy-terminal regions of A α chains, might ameliorate the thrombophilia that accompanies the abnormality.

Acknowledgments

We are most grateful to Karen Mickey Higgins for graphic arts, and to Diane Bartley for skilled technical assistance.

These investigations were supported by National Institutes of Health grants HL-47000 and RR-O1777, and U.S. Department of Energy, OHER.

References

- Ebert, R.F. 1994. Index of Variant Human Fibrinogens. CRC Press, Boca Raton, FL. 423 pp.
- Haverkate, F., and M. Samama. 1995. Familial Dysfibrinogenemia and Thrombophilia. *Thromb. Haemost.* 73:151-161.
- Koopman, J., F. Haverkate, J. Grimbergen, S.T. Lord, M.W. Mosesson, J.P. DiOrio, K.R. Siebenlist, C. Legrand, J. Soria, C. Soria, and J.P. Caen. 1993. The molecular basis for fibrinogen Dusart (A α 554 Arg \rightarrow Cys) and its association with abnormal fibrin polymerization and thrombophilia. *J. Clin. Invest.* 91:1637-1643.
- Soria, J., C. Soria, and J.P. Caen. 1983. A new type of congenital dysfibrinogenemia with defective fibrin lysis-Dusard syndrome: possible relation to thrombosis. *Br. J. Haematol.* 53:575-586.
- Wada, Y., and S.T. Lord. 1994. A correlation between thrombotic disease and a specific fibrinogen abnormality (A α 554 Arg \rightarrow Cys) in two unrelated kindred, Dusart and Chapel Hill III. *Blood.* 84:3709-3714.
- Siebenlist, K.R., M.W. Mosesson, J.P. DiOrio, J. Soria, C. Soria, and J.P. Caen. 1993. The polymerization of fibrinogen Dusart (A α 554 Arg \rightarrow Cys) after removal of carboxy terminal regions of the A α chains. *Blood Coag. Fibrinol.* 4:61-65.
- Lijnen, H.R., J. Soria, C. Soria, D. Collen, and J.P. Caen. 1984. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. *Thromb. Haemostasis.* 51:108-109.
- Collet, J.-P., J. Soria, M. Mirshahi, M. Hirsch, F.B. Dagonnet, J. Caen, and C. Soria. 1993. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. *J. Clin. Invest.* 82:2462-2469.
- Mosesson, M.W., K.R. Siebenlist, J.F. Hainfeld, and J.S. Wall. 1995. The covalent structure of factor XIIIa-crosslinked fibrinogen fibrils. *J. Struct. Biol.* 115:88-101.
- Mosesson, M.W., K.R. Siebenlist, J.P. DiOrio, M. Matsuda, J.F. Hainfeld, and J.S. Wall. 1995. The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and fibrinogen Tokyo II (γ 275 Arg \rightarrow Cys). *J. Clin. Invest.* 96:1053-1058.
- Kudryk, B., J. Reuterby, and B. Blombäck. 1973. Adsorption of plasmin fragment D to thrombin modified fibrinogen-sepharose. *Thromb. Res.* 2:297-304.
- Blombäck, B., B. Hessel, D. Hogg, and L. Therkildsen. 1978. A two-step fibrinogen-fibrin transition in blood coagulation. *Nature (Lond.)* 275:501-505.
- Budzynski, A.Z., S.A. Olexa, and B.V. Pandya. 1983. Fibrin polymerization sites in fibrinogen and fibrin fragments. *Ann. NY Acad. Sci.* 408:301-314.
- MacFarlane, A.S. 1963. In vivo behavior of I¹³¹ fibrinogen. *J. Clin. Invest.* 42:346-361.
- Robbins, K.C., and L. Summaria. 1976. Plasminogen and plasmin. *Methods Enzymol.* 45:257-273.
- Loewy, A.G., K. Dunathan, R. Kriel, and H.L. Wolfinger, Jr. 1961. Fibrinase. I. Purification of substrate and enzyme. *J. Biol. Chem.* 236:2625-2633.
- Lorand, L., and T. Gotoh. 1970. Fibrinoligase. The fibrin stabilizing factor system. *Methods Enzymol.* 19:770-782.
- Kazal, L.A., S. Amsel, O.P. Miller, and L.M. Tocantins. 1963. The preparation and some properties of fibrinogen precipitated from human plasma by glycine. *Proc. Soc. Exp. Biol. Med.* 113:989-994.
- Mosesson, M.W., and S. Sherry. 1966. The preparation and properties of human fibrinogen of relatively high solubility. *Biochemistry.* 5:2829-2835.
- Mosesson, M.W., and J.S. Finlayson. 1963. Subfractions of human fibrinogen. Preparation and analysis. *J. Lab. Clin. Med.* 62:663-674.
- Laemmli, U.K. 1970. Cleavage of structural proteins during assembly of the head of bacteriophage T4. *Nature (Lond.)* 227:680-685.
- Mosesson, M.W., J.S. Finlayson, and D.K. Galanakis. 1973. The essential covalent structure of human fibrinogen evinced by analysis of derivatives formed during plasmin hydrolysis. *J. Biol. Chem.* 248:7913-7929.
- Marder, V.J., A.Z. Budzynski, and H.L. James. 1972. High molecular weight derivatives of human fibrinogen produced by plasmin. *J. Biol. Chem.* 244:4775-4781.
- Mosesson, M.W., J.P. DiOrio, M.F. Müller, J.R. Shainoff, K.R. Siebenlist, D.L. Amrani, G.A. Homandberg, J. Soria, C. Soria, and M. Samama. 1987. Studies on the ultrastructure of fibrin lacking fibrinopeptide B (β -fibrin). *Blood.* 69:1073-1081.
- Mosesson, M.W., J.S. Finlayson, R.A. Umfleet, and D.K. Galanakis. 1972. Heterogeneities of human fibrinogen. I. Structural and related studies of plasma fibrinogens which are high solubility catabolic intermediates. *J. Biol. Chem.* 247:5210-5219.
- Mosesson, M.W., D.K. Galanakis, and J.S. Finlayson. 1974. Comparison of human plasma fibrinogen subfractions and early fibrinogen derivatives. *J. Biol. Chem.* 249:4656-4664.
- Galanakis, D.K., and M.W. Mosesson. 1983. Human fibrinogen heterogeneities: determination of the major A α chain derivatives in blood. *Thromb. Res.* 31:403-413.
- Henschen, A., F. Lottspeich, M. Kehl, C. Southan, and J. Lucas. 1982. Structure-function-evolution relationship in fibrinogen. In *Fibrinogen. Recent Biochemical and Medical Aspects*. A. Henschen, H. Graeff H, and F. Lottspeich, editors. W de Gruyter, Berlin. 67-82.
- Doolittle, R.F., K.G. Cassman, B.A. Cottrell, S.J. Friezner, and T. Takagi. 1977. Amino acid sequence studies on the α chain of human fibrinogen. Covalent structure of the α -chain portion of frag-

ment D. *Biochemistry*. 16:1710–1715.

30. Siebenlist, K.R., D.A. Meh, J.S. Wall, J.F. Hainfeld, and M.W. Mosesson. 1995. Orientation of the carboxy-terminal regions of fibrin γ chain dimers determined from the cross-linked products formed in mixtures of fibrin, fragment D, and factor XIIIa. *Thromb. Haemostasis* 74:1113–1119.

31. Kirschbaum, N.E., M.W. Mosesson, and D.L. Amrani. 1992. Characterization of the γ chain platelet binding site on fibrinogen fragment D. *Blood*. 79:2643–2648.

32. Veklich, Y.I., O.V. Gorkun, L.V. Medved, W. Nieuwenhuizen, and J.W. Weisel. 1993. Carboxyl-terminal portions of the α chains of fibrinogen and fibrin. Localization by electron microscopy and the effects of isolated α C fragments on polymerization. *J. Biol. Chem.* 268:13577–13585.

33. Kanaide, H., and J.R. Shainoff. 1975. Cross-linking of fibrinogen and fibrin by fibrin-stabilizing factor (factor XIIIa). *J. Lab. Clin. Med.* 85:574–597.

34. Dhall, T.Z., W.A.J. Bryce, and D.P. Dhall. 1976. Effects of dextran on the molecular structure and tensile behavior of human fibrin. *Thromb. Haemost.* 35:737–745.

35. Carr, M.E., and D.A. Gabriel. 1980. Dextran-induced changes in fibrin fiber size and density based on wavelength dependence of gel turbidity. *Macromolecules*. 13:1473–1477.

36. Carr, M.E., and D.A. Gabriel. 1980. The effect of dextran 70 on the structure of plasma-derived fibrin gels. *J. Lab. Clin. Med.* 96: 985–993.

37. Ferry, J.D., and P.R. Morrison. 1947. Preparation and properties of serum and plasma proteins. VIII. The conversion of human fibrinogen to fibrin under various conditions. *J. Am. Chem. Soc.* 69: 388–400.

38. Ferry, J.D., S. Shulman, K. Gutfreund, and S. Katz. 1952. The

conversion of fibrinogen to fibrin. XI. Light scattering studies on clotting systems inhibited by hexamethylene glycol. *J. Amer. Chem. Soc.* 74:5709–5715.

39. Mosesson, M.W., N. Alkjaersig, B. Sweet, and S. Sherry. 1967. Human fibrinogen of relatively high solubility. Comparative biophysical, biochemical, and biological studies with fibrinogen of lower solubility. *Biochemistry*. 6:3279–3287.

40. Hasegawa, N., and S. Sasaki. 1990. Location of the binding site “b” for lateral polymerization of fibrin. *Thromb. Res.* 57:183–195.

41. Gorkun, O.V., Y.I. Veklich, L.V. Medved, A.H. Henschen, and J.W. Weisel. 1994. Role of the α C domains of fibrin in clot formation. *Biochemistry*. 33:6986–6997.

42. Mosesson, M.W., J.F. Hainfeld, R.H. Haschemeyer, and J.S. Wall. 1981. Identification and mass analysis of human fibrinogen molecules and their domains by scanning transmission electron microscopy. *J. Mol. Biol.* 153:695–718.

43. Mosesson, M.W., K.R. Siebenlist, D.L. Amrani, and J.P. DiOrio. 1989. Identification of covalently linked trimeric and tetrameric D domains in cross-linked fibrin. *Proc. Natl. Acad. Sci. USA.* 86:1113–1117.

44. Mosesson, M.W., J.P. DiOrio, K.R. Siebenlist, J.S. Wall, and J.F. Hainfeld. 1993. Evidence for a second type of fibril branch point in fibrin polymer networks, the trimolecular branch junction. *Blood*. 82:1517–1521.

45. Gabriel, D.A., K. Muga, and E.M. Boothroyd. 1992. The effect of fibrin structure on fibrinolysis. *J. Biol. Chem.* 267:24259–24263.

46. Carr, M.E., Jr., and B.M. Alving. 1995. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. *Blood Coag. Fibrinol.* 6:567–573.